As Risperdal Lawsuits Mount, Bernstein Liebhard Notes Arkansas Attorney General’s Intention to Seek Reinstatement of Risperdal Fine

The Firm is actively filing Risperdal lawsuits on behalf of men and boys who allegedly suffered gynecomastia, or male breast development, due to their use of Risperdal.

  • Share on TwitterShare on FacebookShare on Google+Share on LinkedInEmail a friend
Free Case Review
Our Firm is representing a number of clients who allege Risperdal caused gynecomastia, or male breast development. These Risperdal lawsuits also make allegations about the drug’s marketing that echo some of those put forth in the Arkansas claim.

New York, New York (PRWEB) April 04, 2014

As Risperdal lawsuits (http://www.risperdallawsuitcenter.com/ ) continue to mount in U.S. courts, Bernstein Liebhard LLP notes that the Arkansas Attorney General has announced his intention to seek the reinstatement of a $1.2 billion Risperdal fine overturned by the state’s Supreme Court last month. According to an April 3rd report from the Associated Press, Arkansas Attorney General Dustin McDaniel told the Arkansas Code Revision Commission on Thursday that he would file a petition asking the Court to revisit the decision.*

According to court records, the $1.2 billion verdict was levied against Johnson & Johnson and its Janssen Pharmaceuticals unit in April 2012, after an Arkansas jury found that the companies had violated state laws governing Medicaid fraud and deceptive trade practice by improperly marketing Risperdal. In overturning the verdict last month, the Supreme Court ruled McDaniel’s office had misapplied the state’s Medicaid fraud law, which a majority of judges said only covers healthcare facilities, and not large pharmaceutical companies. (Ortho-McNeil-Janssen Pharmaceuticals Inc. et al v. Arkansas, Nos. 12-1058, 13-468)

“Our Firm is representing a number of clients who allege Risperdal caused gynecomastia, or male breast development. These Risperdal lawsuits also make allegations about the drug’s marketing that echo some of those put forth in the Arkansas claim. We will be watching this matter closely,” says Bernstein Liebhard LLP, a nationwide law firm representing the victims of defective drugs and medical devices. The Firm is currently offering free legal consultations to men and boys who allegedly developed gynecomastia, or male breast growth, due to their use of Risperdal.

Risperdal Lawsuits
According to court documents, Johnson & Johnson and Janssen have been named in more than 350 Risperdal lawsuits that are currently pending in a consolidated litigation in Pennsylvania's Philadelphia Court of Common Pleas. Dozens of these complaints allege that the use of Risperdal caused gynecomastia in men and boys. Among other things, plaintiffs claim that Risperdal was improperly marketed for off-label use in children long before it was approved for pediatric indications in 2006, and that the companies concealed side effects associated with the medication, including the association between Risperdal and gynecomastia. (Risperdal Litigation, case number 100300296)

The Arkansas lawsuit was not the only time questions were raised about the marketing tactics used to drive sales of Risperdal. On November 4, 2013, the U.S. Department of Justice (DOJ) announced Johnson & Johnson and Janssen had agreed to pay $2.2 billion to settle civil and criminal charges involving the marketing of Risperdal and other medications. Under the terms of the settlement, the drug makers entered a guilty plea to one criminal misdemeanor charge involving the illegal promotion of Risperdal for use in elderly dementia patients. However, they did not admit wrongdoing in resolving civil claims that it improperly marketed Risperdal for use in children. (U.S. District Court, Eastern District of Pennsylvania, 04-cv-1529)

Risperdal users who developed gynecomastia may be entitled to compensation for their medical bills, lost wages, pain and suffering, emotional distress, and other injury-related damages. Learn more about filing a Risperdal lawsuit at Bernstein Liebhard LLP’s website. Free case reviews may also be obtained by calling the Firm directly at 800-511-5092.

*arkansasonline.com/news/2014/apr/03/mcdaniel-ask-court-reconsider-risperdal-ruling/?f=news-arkansas, Associated Press, April 3, 2014

About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993, including those who have been harmed by dangerous drugs, defective medical devices and consumer products. The firm has been named by The National Law Journal to the Plaintiffs’ Hot List, recognizing the top plaintiffs firms in the country, for the past 12 consecutive years. Bernstein Liebhard LLP is the only firm in the country to be named to this prestigious list every year since the list was first published in 2003.

Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
800-511-5092

ATTORNEY ADVERTISING. © 2014 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.

Contact Information:
Felecia L. Stern, Esq.
Bernstein Liebhard LLP
info (at) consumerinjurylawyers (dot) com
http://www.risperdallawsuitcenter.com/
https://plus.google.com/115936073311125306742?rel=author